LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
The excess of said expense, compared to the average cost of neighboring countries, was close to 0.79% of GDP. A Fedesarrollo study stated that the spending on defense and security carried out during 2004 "represented 4.5% of GDP", which does not have precedents in the history of Colombia. This is directly related to the Democratic Security Policy (Política de seguridad democrática) undertaken by the government of then-president Álvaro Uribe, who focused on military strikes on groups outside the law in order to regain security national. For the year 2004, the expenses of the Colombian Government in war and security were 6.59%, placing the country between the tenth that invest the most in war as a proportion of GDP.
== Drug pricing issue and exit in the Swiss market == In July 2025, Roche withdrew Lunsumio from the Swiss market following failed price negotiations with the Swiss Federal Office of Public Health (BAG). The drug had been available since February 2023 through a special "Early Access" program that allowed reimbursement before complete clinical data was available. Under this arrangement, Roche initially covered treatment costs until efficacy was demonstrated, after which the remaining therapy could exceed 100,000 Swiss francs. When Swissmedic extended the temporary authorization in February 2025 due to still-missing complete clinical data from Phase III studies, Roche rejected the previously negotiated pricing model and demanded higher prices. The BAG refused to modify the agreement, citing concerns that exceptions would set a precedent for other pharmaceutical companies and demanding additional efficacy evidence despite the drug showing positive effects in Phase II studies. According to Swissmedic pricing data, a single 60-mg dose (two vials) of Lunsumio costs over 7,000 Swiss francs. The withdrawal was announced to oncologists on July 1, 2025, affecting approximately 24 patients annually who suffer from follicular lymphoma—a slowly progressing cancer of the lymph nodes with about 500 new cases per year in Switzerland. Roche also refused to provide individual case reimbursements—a standard Swiss mechanism for exceptional medical situations.
=== mzAPI === Instead of defining new file formats or writing converters for proprietary vendor formats, a group of scientists proposed a common application program interface to shift the burden of standards compliance to the instruments manufacturers' existing data-access libraries.
Sources: en.wikipedia.org
=== Indirect (unconjugated) === The measurement of unconjugated bilirubin (UCB) is underestimated by measurement of indirect bilirubin, as unconjugated bilirubin (without/yet glucuronidation) reacts with diazosulfanilic acid to create azobilirubin which is measured as direct bilirubin.
== Medical uses == Amoxapine is used in the treatment of major depressive disorder. Compared to other antidepressants it is believed to have a faster onset of action, with therapeutic effects seen within four to seven days. In excess of 80% of patients that do respond to amoxapine are reported to respond within two weeks of the beginning of treatment. It also has properties similar to those of the atypical antipsychotics, and may behave as one and thus may be used in the treatment of schizophrenia off-label. Despite its apparent lack of extrapyramidal side effects in patients with schizophrenia it has been found to worsen motor function in a study of three patients with Parkinson's disease and psychosis.
At the San Sebastián International Film Festival, he was awarded the Donostia Lifetime Achievement Award and became the youngest recipient of the award. The same year, he also starred in the disaster drama film The Impossible opposite Naomi Watts and Tom Holland. In 2013, McGregor starred alongside Meryl Streep and Julia Roberts in August: Osage County, which was based on Tracy Letts's Pulitzer Prize-winning play of the same name. McGregor starred in the action comedy film Mortdecai (2015), alongside Johnny Depp and Paul Bettany. Robbie Collin of The Daily Telegraph felt the film was "psychotically unfunny". He made his directorial debut with American Pastoral (2016), in which he also starred. In 2017, he reprised his role as Mark Renton in T2 Trainspotting. McGregor played and voiced Lumière (originally voiced by Jerry Orbach in the 1991 animated film) in the live-action adaptation of Disney's Beauty and the Beast, directed by Bill Condon, with an ensemble cast featuring Emma Watson and Dan Stevens in leading roles, alongside Luke Evans, Kevin Kline, Josh Gad, Stanley Tucci, Ian McKellen, and Emma Thompson. Filming began in May 2015 at Shepperton Studios in London, and the movie was released in March 2017. He then starred in FX anthology series in the third season of Fargo (both 2017), which garnered him a Golden Globe Award for Best Actor – Miniseries or Television Film for his dual performance of Emmit Stussy and Ray Stussy at the 75th Golden Globe Awards.
Sources: en.wikipedia.org
The modern method of embalming involves the injection of various chemical solutions into the arterial network of the body to primarily disinfect and slow the decomposition process. William Harvey, the 17th century English physician who was the first to detail the system of blood circulation, made his discoveries by injecting colored solutions into corpses. The Scottish surgeon William Hunter was the first to apply these methods to the art of embalming as part of mortuary practice. He wrote a widely read report on the appropriate methods for arterial and cavity embalming in order to preserve bodies for burial. His brother, John Hunter, applied these methods and advertised his embalming services to the general public from the mid-18th century. One of his more notorious clients was dentist Martin Van Butchell. When his wife Mary died on 14 January 1775, he had her embalmed as an attraction to draw more customers. Hunter injected the body with preservatives and color additives that gave a glow to the corpse's cheeks, replaced her eyes with glass eyes, and dressed her in a fine lace dress. The body was embedded in a layer of plaster of Paris in a glass-topped coffin. Butchell exhibited the body in the window of his home and many Londoners came to see it; however, Butchell drew criticism for the display. A rumor, possibly started by Butchell himself, claimed that his wife's marriage certificate had specified that her husband would only have control over her estate after her death for as long as her body was kept unburied.
Serine hydroxymethyltransferase can decompose serine into formaldehyde and glycine, according to the reaction HOCH2CH(NH2)CO2H → CH2O + H2C(NH2)CO2H. Methylotrophic microbes convert methanol into formaldehyde and energy via methanol dehydrogenase: `CH3OH → CH2O + 2e− + 2H+ Other routes to formaldehyde include oxidative demethylations, semicarbazide-sensitive amine oxidases, dimethylglycine dehydrogenases, lipid peroxidases, P450 oxidases, and N-methyl group demethylases. Formaldehyde is catabolized by alcohol dehydrogenase ADH5 and aldehyde dehydrogenase ALDH2.
== Awards and honours == Robinson has received many honors working as a cellular biologist. She was awarded a Wellcome Trust Principal Research Fellowship in 1999 and in 2003 she was appointed Professor of Molecular Cell Biology. She was elected a Fellow of the Academy of Medical Sciences in 2001 and member of the European Molecular Biology Organization in the same year. She was elected a Fellow of the Royal Society (FRS) in 2012. The Wellcome Trust also has funded her research for over 25 years.
distillation The process of separating the component substances of a liquid mixture by exploiting differences in the relative volatility of the mixture's components through selective boiling and subsequent condensation. The apparatus used to distill a substance is called a still, and the re-condensed substance yielded by the process is called the distillate.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.